Patrick  Flume  to  Middle Aged
                            
                            
                                This is a "connection" page, showing publications  Patrick  Flume  has written about  Middle Aged.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.324
         
        
        
     
 
    
        
        - 
            Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. J Cyst Fibros. 2021 03; 20(2):288-294.
            
            
                Score: 0.051
             
- 
            Aerosolized Antibiotics for Patients with Bronchiectasis. Am J Respir Crit Care Med. 2016 Apr 01; 193(7):808-10.
            
            
                Score: 0.037
             
- 
            Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep; 142(3):718-724.
            
            
                Score: 0.029
             
- 
            Patient-reported pain and impaired sleep quality in adult patients with cystic fibrosis. J Cyst Fibros. 2009 Sep; 8(5):321-5.
            
            
                Score: 0.023
             
- 
            Pneumothorax in cystic fibrosis. Chest. 2005 Aug; 128(2):720-8.
            
            
                Score: 0.018
             
- 
            Massive hemoptysis in cystic fibrosis. Chest. 2005 Aug; 128(2):729-38.
            
            
                Score: 0.018
             
- 
            A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. Am J Respir Crit Care Med. 2021 12 01; 204(11):1295-1305.
            
            
                Score: 0.014
             
- 
            Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. Sci Rep. 2021 07 09; 11(1):14232.
            
            
                Score: 0.013
             
- 
            Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. J Cyst Fibros. 2021 01; 20(1):78-85.
            
            
                Score: 0.013
             
- 
            Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 12 15; 198(12):1559-1569.
            
            
                Score: 0.011
             
- 
            Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med. 2017 03 15; 195(6):814-823.
            
            
                Score: 0.010
             
- 
            Relief of the 'air hunger' of breathholding. A role for pulmonary stretch receptors. Respir Physiol. 1996 Mar; 103(3):221-32.
            
            
                Score: 0.009
             
- 
            Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015 Jul; 3(7):524-33.
            
            
                Score: 0.009
             
- 
            Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 07 16; 373(3):220-31.
            
            
                Score: 0.009
             
- 
            Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep; 2(9):738-49.
            
            
                Score: 0.008
             
- 
            Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros. 2013 Jul; 12(4):367-76.
            
            
                Score: 0.007
             
- 
            Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):645-52.
            
            
                Score: 0.007
             
- 
            Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011 Jun; 55(6):2636-40.
            
            
                Score: 0.007
             
- 
            Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011 Jan; 10(1):54-61.
            
            
                Score: 0.006
             
- 
            Cost-effective airway cultures in the cystic fibrosis patient. Am J Otolaryngol. 2009 May-Jun; 30(3):150-2.
            
            
                Score: 0.005
             
- 
            The delta F508 mutation in cystic fibrosis and impact on sinus development. Am J Rhinol. 2007 Jan-Feb; 21(1):122-7.
            
            
                Score: 0.005
             
- 
            Wegener's granulomatosis in patients with rheumatoid arthritis. J Rheumatol. 2003 Sep; 30(9):2064-9.
            
            
                Score: 0.004
             
- 
            Pulmonary complications after esophagectomy. Ann Thorac Surg. 2002 Mar; 73(3):922-6.
            
            
                Score: 0.003
             
- 
            Psychological functioning of adults with cystic fibrosis. Chest. 2001 Apr; 119(4):1079-84.
            
            
                Score: 0.003
             
- 
            Effect of pulmonary rehabilitation on quality of life in patients with COPD: the use of SF-36 summary scores as outcomes measures. J Cardiopulm Rehabil. 2000 Jul-Aug; 20(4):231-4.
            
            
                Score: 0.003
             
- 
            The MUSC lung transplantation program: the first year's experience. J S C Med Assoc. 1995 May; 91(5):223-7.
            
            
                Score: 0.002